Letters sent to healthcare professionals in April 2016

2016-05-10T15:30:08+01:00

In April 2016, letters were sent regarding canagliflozin (Invokana▼, Vokanamet▼), BCR-ABL tyrosine kinase inhibitors, pomalidomide (Imnovid▼), and retigabine (Trobalt)